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Introduction 
Hyperdynamic  circulatory  state  is  a  common  and  long-recognized  feature  of  patients  with 
decompensated chronic liver disease (1). It is characterized by elevated cardiac rate and output and 
reduced  peripheral  vascular  resistance,  with  pooling  of  blood  in  the  splanchnic  and  peripheral 
circulation and effective central hypovolemia. 
The  autonomic  nervous  system  plays  a  central  role  in  modulating  cardiac  performance  and  the 
vasomotor activity in the hyperdynamic circulatory state (2).
 The presence of an autonomic dysfunction (AD) in cirrhosis has been clearly shown through different 
experimental approaches, including the evaluation of the cardiovascular and sudomotor responses to 
physiological  and  pharmacological  stimulation  (3-6),  and  by  showing  a  hyperproduction  of  weak 
adrenergic neurotransmitters (7).
It has also been reported that the severity of AD is proportional to the severity of cirrhosis (5,8), and its 
presence is an indicator of poor prognosis in patients with both early and advanced liver disease (9,10).
In an earlier study from our department, the presence of AD correlated with the occurrence of variceal 
bleed (11).
Heart  rate  variability implies  variations  in  the interval  between consecutive heart  beats  as well  as 
between consecutive instantaneous heart rate, ie, it describes the variations of both instantaneous heart 
rate and RR intervals (12). It is a simple test to assess the function of the autonomic nervous system 
and its modulation on the heart rate.  
Measurement of AD in chronic liver disease, using Heart rate variability (HRV), has been shown to 
correlate with the underlying severity of the liver disease (13). But, there are no studies from India, on 
the impact of Heart rate variability in predicting the severity, prognosis and bleed pattern in patients 
with cirrhosis liver.
                                                          Aim of the study
• To assess Heart rate variability (HRV) as a test for Autonomic nervous system (ANS) function 
in patients with liver cirrhosis, comparing it with healthy controls. 
• To correlate HRV results with the severity of the underlying liver  disease
• To compare HRV outcome between 
– Bleeders and non-bleeders 
– Survivors and non-survivors
Review of literature
Autonomic Nervous System (ANS)
The ANS is predominantly an efferent system transmitting impulses from the central nervous system 
(CNS) to peripheral organs. Its effects include control of Heart rate (HR) and force of heart contraction, 
constriction and dilatation of blood vessels, contraction and relaxation of smooth  muscle in various 
organs, and glandular secretions. Autonomic nerves constitute all of the efferent fibers that leave the 
CNS, except for those that innervate skeletal muscle (14, 15). There are some afferent autonomic fibers 
(ie, from the periphery to the CNS) that innervate the baroreceptors and chemoreceptors in the carotid 
sinus and aortic arch, which are important in the control of HR, blood pressure, and respiratory activity. 
The ANS is divided into two separate divisions, parasympathetic and sympathetic, based on anatomical 
and functional differences (Table 1). 
Parasympathetic Nervous System 
The preganglionic outflow of the parasympathetic nervous system (PNS) arises from the brain stem and 
is known as the craniosacral outflow. The vagus nerve (or Xth cranial nerve) carries fibers to the heart 
and lungs (as well as other organs) and is the primary parasympathetic innervation of these organs. The 
PNS is largely concerned with conservation and restoration of energy by causing a reduction in HR and 
blood pressure and by facilitating digestion and absorption of nutrients and discharge of wastes. The 
chemical transmitter at synapses in the PNS is acetylcholine (Ach); thus, nerve fibers that release Ach 
from  their  endings  are  described  as  cholinergic.  The  specific  Ach  receptors  have  been  further 
subdivided pharmacologically by the actions of the alkaloids muscarine and nicotine on these receptors. 
Postganglionic  parasympathetic  nerve  endings,  the  response  of  which  to  Ach  is  mimicked  by 
muscarine, are referred to as muscarinic Ach receptors, and postganglionic receptors, the response of 
which to Ach is mimicked by nicotine, are termed nicotinic Ach receptors. Vagal tone declines with 
aging,  and  the  only  physiological  stimulus  that  has  been  found  to  increase  vagal  tone  is  regular 
dynamic exercise.
Table 1: Functional consequences of autonomic innervation
Physiologic function Sympathetic Parasympathetic
Heart rate Increased Decreased
Blood pressure Increased Mildly decreased
Bladder Increased sphincter tone Voiding (decreased tone)
Bowel motility Decreased motility Increased
Lung Bronchodilatation Bronchoconstriction
Sweat glands Sweating -
Pupils Dilatation Constriction
Adrenal glands Catecholamine release -
Sexual function Ejaculation, orgasm Erection
Sympathetic Nervous System
The cell bodies of the sympathetic preganglionic fibers are in the lateral horns of spinal segments T1 
through L2, which comprise  the thoracolumbar  outflow of the sympathetic  ganglionic  chains.  The 
adrenal medulla is innervated by preganglionic fibers, and therefore, adrenaline is released from the 
gland  by stimulation  of  nicotinic  Ach receptors.  At  most  postganglionic  sympathetic  endings,  the 
chemical transmitter is noradrenaline, which is present in the presynaptic terminal as well as in the 
adrenal medulla. The synthesis and storage of the catecholamines adrenaline and noradrenaline (which 
are synthesized from the essential amino acid phenylalanine) in the adrenal medulla is similar to that of 
sympathetic postganglionic nerve endings, but most noradrenaline in the adrenal medulla is converted 
to  adrenaline.  The  adrenal  medulla  responds  to  nervous  impulses  in  the  sympathetic  cholinergic 
preganglionic fibers by hormonal secretion. In situations involving physical or  psychological stress, 
much larger quantities are released. In contrast to the parasympathetic system, the sympathetic system 
enables the body to respond to challenges to survival (fight or flight) or situations of hemodynamic 
collapse or respiratory failure. Sympathetic responses include an increase in HR, blood pressure, and 
cardiac output;  a diversion of blood flow from the skin and splanchnic vessels  to those supplying 
skeletal muscle; bronchiolar dilation; and a decline in metabolic activity. The actions of catecholamines 
are  mediated  by α  and  ß  receptors.  ß1-adrenoceptor–mediated  effects  in  the  heart,  which  include 
increased  force  and  rate  of  contraction,  are  differentiated  from  those  producing  smooth  muscle 
relaxation in the bronchi and blood vessels, which are ß2-mediated effects. 
Hemodynamic changes in Chronic liver disease
Hyperdynamic circulation
Hyperdynamic  circulation  is  a  feature  of  patients  with  advanced  cirrhosis,  consisting  of  elevated 
cardiac  rate  and  output  and  reduced  peripheral  vascular  resistance,  so  that  arterial  pressure  is 
tendentially or frankly reduced (1,16). 
An  increase  in  cardiac  output  can  be  attributed  to  an  increase  in  venous  return,  heart  rate  and 
myocardial contractility, all of which are controlled by the autonomic nervous system. Vasodilatation 
(low systemic vascular  resistance),  the presence of arteriovenous communications,  expanded blood 
volume and increased sympathetic nervous activity may further raise the cardiac output; most of these 
pathophysiological mechanisms are active in advanced cirrhosis (16). In the early stages, the presence 
of a hyperdynamic circulation is often not apparent. However, with the progression of the liver disease, 
there is an overall association between the severity of the cirrhosis and the degree of hyperdynamic 
circulation.  Studies  on  circulatory  changes  with  posture  suggest  that  the  patients  are  mostly 
hyperdynamic in the supine position (2).
Blood and plasma volumes are raised in advanced cirrhosis, but the distribution between central and 
non-central vascular areas is unequal (17). Thus, by different techniques it has been established that the 
central and arterial blood volume- that is, the blood volume in the heart, lungs and central arterial tree, 
is  most often decreased,  whereas the non-central  blood volume, in particular  the splanchnic blood 
volume, is increased in animals and patients with cirrhosis (Table 2) (16-18). The effective arterial 
blood volume (ie, the circulatory compartment sensed by baroreceptors) and the central circulation time 
(ie, central blood volume relative to cardiac output) are substantially reduced and bear a significant 
relationship to poorer survival in advanced cirrhosis (19).
Total  vascular  compliance  as  well  as  arterial  compliance  (ie,  an  increase  in  intravascular  volume 
relative to  an  increase in  transmural  blood pressure)  are  increased in  cirrhosis  with  the  degree of 
decompensation (20).
Pathophysiology of splanchnic arteriolar vasodilatation
Arteriolar vasodilatation in cirrhosis and portal hypertension may be brought about by a combination of 
overproduction of circulating vasodilators, vasodilators of intestinal or systemic origin, vasodilators 
that  escape degradation in  the diseased liver  or bypass  the liver  through portosystemic collaterals, 
reduced resistance to vasoconstrictors and increased sensitivity to vasodilators (16).
According  to  ‘‘the  arterial  vasodilation  hypothesis’’,  splanchnic  arteriolar  vasodilation  leads  to 
reduction of the systemic vascular resistance, central arterial underfilling with effective hypovolaemia, 
activation  of  vasoconstrictor  systems,  such  as  the  sympathetic  nervous  system (SNS),  the  renin–
angiotensin–aldosterone system (RAAS), vasopressin, endothelins (ETs) and neuropeptide Y (20).
This  leads  to  the  development  of  a  hyperkinetic  circulatory  state.  The  predominantly  splanchnic 
vasodilation in cirrhosis precedes the increase in cardiac output and heart rate With the progression of 
the disease, the splanchnic vasodilatation becomes more pronounced and the hyperdynamic circulation 
may no longer be sufficient to correct the effective hypovolaemia (21). The splanchnic circulation is 
less sensitive to the effects of angiotensin II, noradrenaline and vasopressin because of the surplus of 
vasodilators  which  may  play  a  role  in  the  development  of  the  vascular  hyporesponsiveness  to 
vasoconstrictors (22). The arterial blood pressure is mainly maintained by vasoconstriction in the renal, 
cerebral and hepatic vascular beds; where there seems to be a diminished release of nitric oxide (NO) 
from endothelial cells (23). To explain the vasodilatation in the systemic circulation, recent research 
has focused especially on substances such as NO, CGRP and adrenomedullin, but natriuretic peptides, 
interleukins, hydrogen sulphide, ETs and endocannabinoids have also been implicated (20). Systemic 
NO production is increased and precedes the development of the hyperdynamic circulation in cirrhosis, 
thereby playing a major role in the arteriolar and splanchnic
Table 2: Circulatory changes in specific vascular beds in cirrhosis
Systemic circulation Changes
Plasma volume 
Total blood volume 
Non-central blood volume 
Central and arterial blood volume 
Arterial blood pressure 
Systemic vascular resistance
Heart
Heart rate 
Cardiac output 
Left atrial volume 
Left ventricular volume 
Total vascular compliance
Arterial compliance 
Renal circulation
Renal blood flow
Glomerular filtration rate 
Hepatic and splanchnic circulation
Hepatic blood flow
Hepatic venous pressure gradient 
Postsinusoidal resistance
vasodilation and vascular hyporeactivity (23).
Thus,  the  excess  of  vasodilators  combined  with  an  inadequate  haemodynamic  response  to 
vasoconstrictors may explain the vasodilatatory state and vascular hyporeactivity in cirrhosis combined 
with a hyperdynamic circulation, but the pathophysiological mechanisms behind the development of 
the hyperdynamic circulation in cirrhosis may be multifarious (Table 3).
Hepatic circulation
In healthy subjects, the hepatic blood flow equals the splanchnic blood flow, but patients with portal 
hypertension have a substantial portosystemic collateral circulation, and an increased mesenteric inflow 
of up to several litres per minute has been reported (table 2). Thus, a large part of the increased cardiac 
output is returned through portosystemic collaterals. The azygous blood flow is especially important, as 
the azygous vein drains oesophageal varices and an increase in azygous flow is associated with an 
increased risk of variceal bleeding. there seems to be a defective sinusoidal eNOS-derived production 
of
NO. In addition, recent investigations of endogenous vasoactive substances have focused especially on 
ET-1, angiotensin II,  catecholamines and leukotrienes in the increased hepatic-sinusoidal resistance 
(22).  The  haemodynamic  imbalance  with  a  predominant  sinusoidal  constriction  may  contribute 
significantly to the development of portal hypertension
Volume distribution and circulatory dysfunction
Imbalance between vasodilating and vasoconstricting forces in cirrhosis contributes to an abnormal 
distribution of volume, vascular resistance and flow. Although the cardiac output is increased, thereby 
reflecting  substantial  vasodilatation,  it  covers  hyperperfused,  Table  3:  Pathophysiological 
components in the hyperdynamic circulation and cardiovascular dysfunction in cirrhosis
• Peripheral and splanchnic arterial vasodilatation
 Baroreceptor-induced increase in heart rate
• Autonomic dysfunction
 Increased sympathetic nervous activity
 Vagal impairment
• Alterations in cardiac preload
 Increased portosystemic shunting
 Increased blood volume
 Effects of posture
 Decreased blood viscosity
• Alterations in oxygen exchange
 Anaemia
 Hypoxaemia
 Hepatopulmonary syndrome
 Portopulmonary hypertension
normoperfused and hypoperfused vascular beds.  Thus,  in the kidney,  vasoconstriction prevails  and 
plays a pivotal role along with the development of hepatic decompensation.
Liver  dysfunction,  central  hypovolaemia,  arterial  hypotension  and  neurohumoral  activation  of 
particularly the RAAS and SNS with renal  vasoconstriction  is  of  major  importance (20,  21).  The 
increased plasma volume in cirrhosis should therefore be considered secondary to the activation of 
neurohumoral mechanisms consequent on mainly splanchnic vasodilatation, low arterial blood pressure 
and reduced central and arterial blood volume (Table 3).
Central hypovolaemia and arterial hypotension may be ameliorated by infusion of plasma expanders. 
Irrespective of severity, volume expansion produces a rise in stroke volume and cardiac output. In early 
cirrhosis there is a proportional expansion of the central and noncentral parts of the blood volume, 
whereas in late cirrhosis, expansion is mainly confined to the noncentral part, with a proportionally 
smaller  increase in cardiac output,  probably because of cardiac dysfunction and abnormal vascular 
compliance (20).
When therapeutic paracentesis is done in decompensated cirrhosis without administration of plasma 
expanders,  about  75%  of  patients  will  develop  what  is  termed  paracentesis  induced  circulatory 
dysfunction. This condition is characterized by a pronounced activation of the RAAS and SNS, which 
reflects  central  hypovolaemia.  It  is  mainly  caused  by  a  paracentesis-induced  splanchnic  arteriolar 
vasodilatation and brings about a further reduction in the systemic vascular resistance. Intravenous 
infusion of albumin has been shown to prevent complications caused by circulatory dysfunction and 
may prevent development of renal failure and rapid occurrence of ascites, and prolong survival (24). 
Recent studies have shown, however,  that  administration of vasoconstrictors such as terlipressin or 
noradrenaline may be effective alone or especially in combination with albumin. Paracentesis-induced 
circulatory dysfunction is thus an example of a cirrhotic condition where complications attributable to a 
potentially reduced effective blood volume can be prevented by a specific volume expansion. 
The deterioration of the liver function is followed by a decreased renal blood flow and glomerular 
filtration rate, and increased sodium and water reabsorption, and may progress into the hepatorenal 
syndrome, a functional and potentially reversible renal impairment in severely ill patients (22). Studies 
in  non-azotaemic  cirrhotic  patients  suggest  that  circulatory dysfunction  with  a  decrease  in  cardiac 
output combined with splanchnic arterial vasodilatation and activation of the RAAS contribute to renal 
dysfunction and the hepatorenal syndrome (21, 24). Angiotensin II mainly acts on the efferent arteriole, 
and a low dose of an ACE inhibitor may induce a significant reduction in glomerular filtration and a 
further reduction in sodium excretion, even in the absence of a change in arterial blood pressure. This 
suggests that the integrity of the RAAS is important for the maintenance of renal function in cirrhotic 
patients and that RAAS overactivity does not solely contribute to the adverse renal vasoconstriction. 
The circulation of the extremities
The cutaneous and muscular  circulations  may be increased  in  patients  with cirrhosis  (20).  Palmar 
erythema,  spider  naevi  and  potatory  face  were  early  recognised  as  clinical  signs  of  cutaneous 
hyperperfusion.  These types  of circulatory abnormalities  illustrate  capillary hyperperfusion and the 
presence of arteriovenous fistulae.
Abnormalities in the regulation of the circulation
Autonomic dysfunction 
Cirrhosis is often associated with autonomic neuropathy which has become evident from studies of 
haemodynamic responses  to  standard cardiovascular  reflex  tests,  such  as  heart  rate  variability and 
isometric exercise (2, 11, 25). Most studies on these issues have found a high prevalence of autonomic 
dysfunction in cirrhosis with associations with liver dysfunction and survival (13, 26). Most studies 
have focused on defects in the SNS, but the importance of vagal impairment for sodium and fluid 
retention has been shown (2, 25, 26). Sympathetic responses to exercise are clearly impaired (27, 28). 
Similarly,  blood  pressure  responses  to  orthostasis  are  impaired,  probably  because  of  a  blunted 
baroreflex function in advanced cirrhosis (29). Abnormal cardiovascular responses to vasoconstrictors 
have  been  reported  in  patients  with  cirrhosis  (20),  and  there  is  experimental  evidence  that  haem 
oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with 
ascites (30). Administration of captopril partly corrects the parasympathetic dysfunction in cirrhosis, 
which  indicates  that  the  vagal  component  is  to  a  certain  extent  caused  by neuromodulation  with 
angiotensin II (26). Involvement of the RAAS is also supported by data that show normalisation of 
cardiac responses to postural changes after administration of canrenone, an aldosterone antagonist, to 
compensated  cirrhotic  patients  (31).  Interestingly,  the  vasoconstrictor  hyporeactivity  seems  to  be 
reversible  by such antioxidants  as  vitamin C,  which  indicates  that  oxidative stress  plays  a  role  in 
vascular hyporeactivity and that antioxidant therapy could possibly have a role in these complications 
in cirrhosis (32). The pathophysiological basis underlying the autonomic dysfunction in cirrhosis is 
unknown, but relationships to the severity of the liver disease, mortality and reversibility after liver 
transplantation point to hepatic metabolism and increased NO production, and reduced vasoconstrictor 
sensitivity with postreceptor defects. This provides some explanation for the vascular hyporeactivity in 
cirrhosis.
Figure 1: Schematic flow chart representing the hemodynamic changes in Cirrhosis.
Central  blood volume (CBV),  cardiac  output  (CO),  heart  rate  (HR),  plasma volume (PV),   Blood 
volumes (BV), renal vascular resistance (RVR), renal blood flow (RBF), systemic  Vascular resistance 
(SVR), Mean arterial pressure (MAP), SNS, sympathetic nervous  system; RAAS, renin–angiotensin–
aldosterone system; AVP, arginine vasopressin; ET, endothelin.
Arterial blood pressure and baroreceptor function in cirrhosis 
The level of the arterial blood pressure, which depends on the cardiac output and the systemic vascular 
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resistance, is kept low normal in cirrhosis as a circulatory compromise between the vasodilatating and 
counter-regulatory vasoconstricting forces affecting both vascular resistance and arterial compliance. 
There is  a  relationship between the degree of  arterial  hypotension in  cirrhosis  and the severity of 
disease, signs of decompensation, and survival (19, 20). SNS, RAAS, vasopressin and ET-1 are all 
important vasoconstrictors involved in the maintenance of the arterial blood pressure in cirrhosis (20). 
Some  of  the  potent  vasodilators  including,  Nitric  oxide  (NO),  endocannabinoids,  endotoxins  and 
andamide may contribute to the hyperkinetic state and arterial hypotension in cirrhosis (33, 34). The 
arterial  blood pressure possesses a circadian variation.  In cirrhosis, the arterial  blood pressures are 
reduced during the day, whereas at night the values are normal, which indicates an abnormal blood 
pressure regulation (35). Whereas the baroreflex sensitivity (BRS) may be normal in early cirrhosis 
(36), there is substantial evidence that BRS is impaired in patients with advanced disease (37, 38). 
Together with a flat blood pressure/heart rate slope as found during 24 h ambulatory blood pressure 
monitoring, the low BRS contributes to the dysregulation of the arterial blood pressure, although the 
precise mechanism is unknown (35, 38).
Evaluation of the Autonomic function system  
Failure or dysfunction of some portion of the ANS can affect various bodily functions, and a variety of 
symptoms  may  be  attributable  to  autonomic  dysfunction.  Common  symptoms  of  autonomic 
dysfunction are listed in the table. The autonomic symptoms recognized by clinicians most commonly 
are those which relate to failure of cardiovascular control (41). 
Table 4: Common Symptoms of Autonomic Dysfunction 
• Postural hypotension with symptoms (dizziness or fainting on standing)
• Gastric symptoms: gastric retention, nausea nd vomiting, postprandial epigastric bloating, early 
satiety
• Bowel disorders: nocturnal diarrhea, altered bowel habits, fecal incontinence
• Sweating disorders: Hypohidrosis, hyperhidrosis, gustatory diaphoresis
• Impotence (males)
• Dry eyes/mouth
• Failure of papillary accommodation (blurring of vision)
• Bladder dysfunction: urinary retention, impairment of bladder sensation
Assessment of ANS function
Since many of the disorders of ANS function are manifested by effects on heart rate and blood pressure, several techniques 
have been devised for assessment of these functions.
Autonomic function testing laboratories have evolved over the years and equipments have been developed that allow for 
detailed and rather elaborate analysis techniques. The testing modalities available most widely are those that record heart 
rate and blood pressure. Testing protocols which allow for evaluation of both the sympathetic and parasympathetic arms of 
baroreflexes have been devised, and many are now relatively standardized (39, 40, 41). 
Physiological tests that assess the SNS function
1) BP response to sustained handgrip
The blood pressure of the patient is taken three times before the manoeuvre with the help of a modified 
sphygmomanometer.  The  patient  is  asked  to  grip  the  inflatable  rubber  bag  and  apply  maximum 
voluntary  pressure  possible.  A  reading  from  the  attached  mercury   manometer  is  taken  during 
maximum  voluntary  contraction.  Thereafter,  the  patient  is  asked  to  maintain  30%  of  maximum 
voluntary contraction for as long as possible up to five minutes. Blood pressure is measured at one 
minute intervals during the handgrip. The result is expressed as the difference between the highest 
diastolic blood pressure during the handgrip exercise and the mean of the three diastolic blood pressure 
readings before the handgrip began.
Normal response is an increase in diastolic BP by ≥ 16 mm Hg. SNS dysfunction is said to be present, 
if the raise in diastolic BP is < 10 mm Hg.
2) BP response to standing
This test measures the subject’s blood pressure with a sphygmomanometer while he was lying quietly 
and one minute  after  he  is  made to  stand up.  The  postural  fall  in  blood pressure  is  taken  as  the 
difference between the systolic pressure lying and the systolic blood pressure standing.  The test  is 
repeated three times and the mean is calculated.
An abnormal response is defined as a fall in systolic BP by atleast 20 mm Hg and in diastolic BP by at 
least 10 mm Hg.
3) BP response to immersion of hand in cold water 
The  patient  is  asked to  immerse  the  hand in  ice  water  (1-4ºC) for  one minute.  Blood pressure is 
recorded in  the  other  arm at  the end of  one minute.  Systolic  and diastolic  BP rise  by 10-20 mm 
normally. Afferent for this pathway is the spinothalamic tract. 
5) Sweat response
QSART: Quantitative Sudomotor Axon Reflex test is a measure of the regional autonomic function 
mediated by acetyl choline induced sweating. A reduced or absent response indicates a lesion of the 
post ganglionic sudomotor neuron. 
TST: Thermoregulatory sweat test is a qualitative measure of regional sweat production in response to 
an elevation in body temperature. An indicator powder placed on the anterior body surface changes 
colour with sweat production during temperature elevation. 
Combining QSART and TST results will determine the site of lesion. A postganglionic lesion is present 
if both QSART and TST show absent sweating. In a preganglionic lesion, QSART is intact, but TST 
shows anhidrosis.
Physiological tests that assess the PNS function
1) Heart rate response to long valsalva maneuver
The subject is  seated quietly and then asked to blow into a mouthpiece attached to  a manometer, 
holding it at a pressure of 40 mm Hg for 15 seconds while a continuous electrocardiogram (ECG) is 
recorded. The manoeuvre is repeated three times with one minute interval in between and results are 
expressed as:
Valsalva  ratio  =  longest  R-R  interval  after  the  manoeuvre  ÷  shortest  R-R  interval  during  the 
manoeuvre.
The mean of the three Valsalva ratios is taken as the final value. Normal ratio is ≥ 1.21 and PNS 
dysfunction is said to be present if the ratio is < 1.10. 
2) Heart rate variation during deep breathing
The subject is asked to breathe deeply at six breaths/min (five seconds “in” and five seconds “out”) for 
one minute. An ECG is recorded throughout the period of deep breathing and onset of each inspiration 
and expiration  is  marked on ECG paper.  The  maximum and minimum R-R intervals  during each 
breathing cycle are measured with a ruler and converted to beats/min. The results of the test were 
expressed  as  the  mean  of  the  difference  between  maximum and  minimum heart  rates  for  the  six 
measured cycles in beats/min.
Normal response is > 15 beats per minute. PNS dysfunction is present if the difference is < 10 beats per 
minute. 
3) Immediate heart rate response to standing
The  test  is  performed  with  the  subject  lying  quietly  on  a  couch  while  the  heart  rate  is  recorded 
continuously on an electrocardiograph. The patient was then asked to stand unaided and the point at 
starting to stand was marked on ECG paper. The shortest R-R interval at or around the 15th beat and 
the longest R-R interval at around the 30th beat after starting to stand are measured with a ruler. The 
characteristic heart rate response is expressed by 30:15 ratios. 
Normal ratio is > 1.04 and PNS dysfunction is present, if the ratio is < 1.00. 
Pharmacological tests
Pharmacological assessments can help localize an autonomic defect to the central or peripheral nervous 
system. 
1) Measurement of plasma Norepinephrine (NE) level in supine position and 5 min after standing. 
Supine values are reduced in postganglionic disorders (eg: autonomic neuropathy) and may fail to 
raise on standing in pre or postganglionic disorders
2) Administration  of  Tyramine  (releases  NE  from  postganglionic  terminals)  and  phenylephrine 
(denervation supersensitivity- directly acting α1- agonist) is often used to evaluate postganglionic 
adrenergic function. 
Disadvantages of the standard tests
• Some of the tests are provocative that require a stimulus (cold pressor)
• Cumbersome to perform and interpret (eg: valsalva ratio)
• Difficult to reproduce
Advantage of the standard tests
• Can help localize the site of the autonomic neuropathy (whether peripheral or central)
The  latest  development  in  the  assessment  of  ANS  function  includes  the  analysis  of  heart  rate 
variability.
HEART RATE VARIABILITY
Introduction
The heart rate and rhythm are largely under the control of autonomic nervous system. Heart 
rate variability (HRV) is the oscillations in the interval between consecutive heart beats as well as 
oscillations  between  consecutive  instantaneous  heart  rate,  ie,  it  describes  the  variations  of  both 
instantaneous heart rate and RR intervals (from the electrocardiogram tracing). Other terms have been 
used in the literature include, cycle length variability, heart period variability, RR variability, and 
RR interval tachogram, and they, more appropriately emphasize the fact that it is the interval between 
consecutive beats that is being analyzed rather than the heart rate per se (12). 
Back ground
The clinical use of HRV was well recognized, when Hon and Lee, in 1965 (42), showed that, fetal 
distress was preceded by alterations in HRV before any notable change occurred in the heart rate itself. 
During 1970’s , Ewing et al (39) made simple bedside test of short term RR difference to detect a 
neuropathy in diabetic patients. The association of higher post-infarction mortality with reduced HRV 
was later shown by Wolf et al (43). In 1981 Akselrod et al (44) introduced first power spectral analysis 
of heart rate fluctuations to quantitative evaluation. 
The clinical importance of HRV became apparent in the late 1980s when it was confirmed that HRV 
was a strong and independent predictor of mortality following an acute myocardial infarction (45). 
With  the  availability  of  new,  digital,  high  frequency,  24-h  multi-channel  electrocardiographic 
recorders,  HRV  has  the  potential  to  provide  additional  valuable  insight  into  physiological  and 
pathological conditions and to enhance risk stratification.
The European society of Cardiology and North American society of pacing and electrophysiology have 
contributed a Task force to develop appropriate standards to measure HRV, which has been followed in 
this study (12). 
Figure 2: Flow chart summarizing individual steps used when recording and processing the ECG 
signal in order to obtain data for HRV analysis
 
Measurement of heart rate variability
Time domain methods
Variations in heart rate may be evaluated by a number of methods. Perhaps the simplest to perform are 
the time domain measures. With these methods either the heart rate at any point in time or the intervals 
between successive normal complexes are  determined.  In a continuous electrocardiographic (ECG) 
record, each QRS complex is detected, and the so-called normal-to-normal (NN) intervals (that is all 
intervals  between  adjacent  QRS  complexes  resulting  from  sinus  node  depolarizations),  or  the 
instantaneous heart rate is determined. Simple time-domain variables that can be calculated include the 
mean NN interval, the mean heart rate, the difference between the longest and shortest NN interval,
the difference between night and day heart rate, etc.
Other time domain measurements that can be used are variations in instantaneous heart rate secondary 
to respiration, tilt, Valsalva manoeuvre, or secondary to phenylephrine infusion. These differences can 
be described as either differences in heart rate or cycle length. The important time domain measures 
are: 
• Mean R-R (msec): Mean of the normal-to-normal (N-N) interbeat interval.
• SDNN:  Standard  deviation  (SD)  of  all  the  R-R  intervals  in  a  given  period,  expressed  in 
milliseconds.
• SDANN (msec): Standard deviation of the average of N-N intervals for each 5-min period over 
24  hr.  SDANN  is  mainly  accepted  to  represent  the  sympathetic  component  of  autonomic 
function.
• r-MSSD (msec): Root mean square successive differences (the square root of the mean of the 
sum of the squares of differences between adjacent N-N intervals). 
• pNN50 (%): Percentage of adjacent N-N intervals that are >50 msec apart (pNN50). NN50 is 
the number of interval differences of successive NN intervals  >50 msec and pNN50 is the 
proportion derived by dividing the NN50 by the total number of NN intervals. pNN50 and r-
MSSD are mainly accepted to represent the parasympathetic component of autonomic function. 
Frequency domain methods 
The second method of assessing HRV is by the use of power spectral density analysis or frequency 
domain analysis. PSD analysis provides the basic information of how power (ie variance) distributes as 
a function of frequency. Power spectral analysis plots the distribution (spectra) of HR oscillations in the 
frequency domain by mathematically transforming sequential R-R intervals on the electrocardiogram 
into specific frequency components. 
Methods for the calculation of PSD may be generally classified as non-parametric and parametric. In 
most  instances,  both  methods  provide  comparable  results.  The  advantages  of  the  non-parametric 
methods are: (a) the simplicity of the algorithm employed (Fast Fourier Transform -FFT- in most of the 
cases) and (b) the high processing speed.
Fast Fourier transform algorithm can plot the relative energy of different frequency components of 
HRV. The Fourier transform is based on the Fourier theorem, which states that any periodic signal can 
be expressed as a sum of an infinite set of sine and cosine functions with different characteristic periods 
of oscillation and different weighting coefficients. The Fourier transform projects the complex periodic 
oscillation in R-R interval  onto each of these periodic  basis  functions in  much the same way that 
vectors in 3 dimensional space are projected onto the 3 basis vectors that define our visual space. The 
relative power of each point in the frequency domain subsequently can be obtained.
Spectral components
The  three  main  components  that  are  distinguished  in  a  spectral  calculation  from short  term ECG 
recording are (44) 
VLF - Very low frequency 
LF - Low frequency
HF - High frequency
The distribution of power and central frequency of LF and HF are not fixed but may vary in relation to 
changes in autonomic modulations of the heart period (46). The physiological explanation for VLF 
component is much less defined and the existence of a specific physiological process attributable to 
these heart period changes might even be questioned. Thus VLF assessed from short-term recordings 
(e.g. 5 min) is a dubious measure and should be avoided when interpreting the Power spectral density 
(PSD) of short-term ECGs.
The measurement of VLF, LF and HF power are usually made in absolute values of power (millisecond 
squared). Their frequency range is given as follows 
Range (Hz)
VLF 0.0 - 0.04
LF 0.04 - 0.15
HF 0.15 - 0.4
LF and HF are also measured in normalized units (47), which represent the relative value of each 
power component in proportion to the total power minus the VLF component. So the representation of 
LF and HF in normalized units emphasizes the controlled and balanced behavior of the two branches of 
ANS. Moreover, normalization tends to minimize the effect on the values of LF and HF components of 
the changes in total power. Nevertheless, n.u should be always quoted with absolute values of LF and 
HF power in order to describe in total the distribution of power in spectral components. In this study, 
we have quoted absolute value for LF and HF and also the normalized units for LF and HF. The ratio 
of LF to HF gives the autonomic modulation. If the modulations are constant, the interpretations of the 
results  of  frequency  analysis  are  well  defined.  In  our  physiological  mechanism  the  heart  period 
modulations  are  taking  place  every  movement  and  so  these  changes  are  seen  in  LF  and  HF 
components. 
Figure 3: HRV analysis with the Power Spectral Density (PSD) of a healthy person in supine 
(left) and upright (right) posture, showing the VLF, LF and HF components.  LF: dark shaded 
area; HF: light shaded area, VLF: white area  
Thus spectral analysis are taken on the entire 24-hrs period as well as spectral results are obtained from 
shorter segments (5 min) averaged over entire 24hrs also (48). In the present study, we have used short 
term  (5  min)  HRV  analysis.  It  should  be  remembered  that  the  components  of  HRV  provide 
measurement of the degree of autonomic modulation rather than of the level of autonomic tone. 
Physiological correlations of HRV
An understanding of the modulatory effects of neural mechanisms on the sinus node has been enhanced 
by  spectral  analysis  of  HRV  (47).  The  efferent  vagal  activity  is  a  major  contributor  to  the  HF 
component,  as  seen  in  clinical  and  experimental  observations  of  autonomic  maneuvers  such  as 
electrical vagal stimulation, muscarinic receptor blockade, and vagotomy. More controversial is the 
interpretation the LF component which is considered by some (49, 50, 51) as a marker of sympathetic 
modulation (especially when expressed in normalized units) and by others (52) as a parameter that 
includes  both  sympathetic  and  vagal  influence.  This  discrepancy is  due  to  the  fact  that  in  some 
conditions  associated  with  sympathetic  excitation,  a  decrease  in  the  absolute  power  of  the  LF 
component  is  observed.  It  is  important  to  recall  that  during  sympathetic  activation  the  resulting 
tachycardia is usually accompanied by a marked reduction in total power, whereas the reverse occurs 
during vagal activation. When the spectral components are expressed in absolute units (milliseconds 
squared),  the changes  in  total  power,  influence LF and HF in the same direction and prevent  the 
appreciation of the fractional distribution of the energy. This concept is exemplified in showing the 
spectral  analysis  of  HRV  in  a  normal  subject  during  control  supine  condition  and  900 head-up 
tilt(Montano  et  al  1994).  Because  of  the  reduction  in  total  power,  LF  appears  as  unchanged  if 
considered in absolute units. However, after normalization an increase in LF becomes evident. Similar 
results apply to the LF/HF ratio also.
LF and HF can increase under different conditions. An increased LF (expressed in normalized units) is 
observed during 900 tilt, standing, mental stress, and moderate exercise in healthy subjects, and during 
moderate hypotension, physical activity, and occlusion of a coronary artery or common carotid arteries 
in conscious dogs. Conversely, an increase in HF is induced by controlled respiration, cold stimulation 
of the face, and rotational stimuli.   To conclude HRV analysis has got wide application in clinical 
medicine  such  as  diabetic  neuropathy,  Post  Myocardial  infarction  (sudden  death,  malignant 
arrhythmias),  autonomic  function  disturbances,  myocardial  dysfunctions,  CVS drug therapy,  vagal 
dominance identification, exercise training and many other clinical disorders. 
Advantages of HRV analysis over standard autonomic function tests
• Single test gives information on both the sympathetic and the parasympathetic nervous system 
function
• Easy to perform and to interpret for the clinician
• Patient friendly (no need for provocative stimuli)
• Easily reproducible
Disadvantage of HRV analysis over standard autonomic function tests
• Can not localize the site of autonomic neuropathy (whether central or peripheral)
Definitions and Interpretations
• Mean RR interval: Mean of all the R-R intervals
• Parasympathetic function
– SDNN : SD of N to N (R-R) intervals
– HF power (ms2;150-400 mHz)
– HF (normalized units): HF (power) ÷ [LF + HF (power) ]
• Sympathetic and parasympathetic function: LF power (ms2; 4-150mHz): Indicates sympathetic 
more than parasympathetic function
• Sympathetic function: LF (normalized units): LF (power) ÷ [LF + HF (power)] 
Effects of ANS dysfunction on the natural history of cirrhosis
The prevalence autonomic dysfunction (AD) in cirrhosis has varied from 8% - 80% in different series 
(9, 53-57), depending on the underlying severity of liver disease.
ANS dysfunction and the etiology of liver disease
Autonomic nervous dysfunction is  a known complication of  diabetes  (39)  and alcohol  abuse (58). 
Autonomic  damage  is  expected  in  some  patients  with  alcohol  related  cirrhosis  since  autonomic 
neuropathy,  especially  of  vagal  origin,  is  seen  in  chronic  alcoholics  (58).  However,  it  is  well 
established from studies that AD occurs irrespective of the etiology of liver disease: ethanol or non-
ethanol related (10, 40, 55).  
ANS dysfunction and severity of liver disease 
Hendrickse et al in 1993 (59), described that chronic liver disease is accompanied by a number of 
circulatory  changes  including  impairment  of  cardiovascular  autonomic  reflexes.  This  occurs 
irrespective  of  the  aetiology of  liver  disease,  increases  in  prevalence  and severity  with  worsening 
hepatic  function,  and  is  related  at  least  in  part  to  an  autonomic  neuropathy.  Parasympathetic 
abnormalities predominate and, although largely subclinical, they may play a role in the altered fluid 
homeostasis and neurohumoral disturbances associated with cirrhosis. On prospective follow up, the 
presence of autonomic impairment was associated with a five-fold increased mortality, largely from 
sepsis and variceal haemorrhage. Defective responses to such stressful events as a result of an afferent 
defect could possibly explain these findings.
Fleckenstein et  al  (10) showed that  the prevalence of AD was 14.3% in Child’s A, 31.3% in 
Child’s B, and 60%Child’s C patients. Six patients died during a median observation period of 
10months,  and  all  had  AD.  On  the  basis  of  this  observation,  they  suggested  that 
consideration should be given for early liver transplantation in patients with advance liver 
disease and autonomic neuropathy
Fleisher et al (60), in a longitudinal study to determine whether the severity of liver disease correlated with measures of 
heart rate variability, studied 21 patients being evaluated for liver transplantation. Heart rate variability was determined for a 
series of 500 consecutive R-R intervals during quiet breathing. Standard deviation, pNN50, a marker of parasympathetic 
function, and approximate entropy (ApEn), a recently described measure of regularity, were calculated. Four standard tests 
of autonomic function were also performed. pNN50 was significantly reduced in all liver disease patients compared to 
controls (P < 0.05). Both standard deviation and ApEn were significantly reduced in Child's class C patients suggesting a 
generalized dysfunction in cardiovascular homeostasis. ApEn was significantly lower in the nonsurvivors during follow-up 
than the survivors (P < 0.05). The authors concluded that, increasing severity of liver failure is associated with a reduction 
in total heart rate variability and regularity & measurement of heart rate variability offers a simple, noninvasive means of 
assessing the cardiovascular and autonomic effects of liver disease, particularly in those awaiting liver transplantation.
Coelho et al (61), evaluated autonomic function in  22 cirrhotic patients (55% alcoholic cirrhosis) by using the 24 hour 
Heart Rate Variability study. The cirrhotic patients showed severe decrease in Heart Rate Variability when compared to 
healthy volunteers. The spectral analysis revealed marked decrease of average total power, with reduction of all components 
(VLF, LF, HF), in the absence of significant difference in LF/HF ratio. Ascites had relationship with more pronounced 
autonomic impairment. On the other hand, alcohol related etiology did not influence Heart Rate Variability parameters. The 
authors, found significant positive correlations between SDNN (dependent variable) and Prothrombin activity (r = 0.64; p = 
0.001), as well as with Serum Albumin (r = 0.40; p = 0.05), but not with Total Bilirubin (r = -0.14; p = 0.51). Prothrombin 
activity  was  the  only  independent  predictor  of  autonomic  dysfunction.  The  authors  concluded  that  the  greater  the 
hepatopathy severity,  the greater the heart rate variability impairment. Hepatocellular dysfunction indicators have more 
accuracy to demonstrate autonomic disturbances than cholestasis indicators.
Iga et al (62), evaluated abnormalities of autonomic nervous function in 50 patients with liver cirrhosis 
by  123I-metaiodobenzylguanidine  (MIBG)  myocardial  scintigraphy  and  heart-rate  variability. 
Echocardiogram,  urinary nitrite  and  nitrate,  and cathecholamines  were  examined.  Washout  rate  of 
MIBG,  LF/HF,  and  blood  levels  of  norepinephrine  increased  and  HF  power  decreased  with  the 
progression of Liver Cirrhosis. However, the urinary secretion of nitrite and nitrate were significantly 
increased only in cirrhotic patients with Child C. The authors concluded that autonomic abnormalities 
appear  early  in  cirrhotics,  and  that  these  abnormalities  can  be  detected  by  MIBG  myocardial 
scintigraphy and analysis of heart-rate variability. 
Ates et  al  (12),  analyzed HRV using 24-hr ECG recording in 30 cirrhotic  patients  and 28 normal 
controls. The changes in HRV parameters involving the time domain measures were analyzed. The 
time-domain measures of HRV in cirrhotic patients were significantly reduced compared with those in 
the control group (for all parameters; P < 0.001). The severity of disease was associated with reduced 
HRV measures (for all parameters; P < 0.001). After the 2-year follow-up periods, HRV measurements 
in cirrhotic patients were significantly much lower in nonsurvivors than in survivors (P<0.001 for all). 
The authors concluded, that increasing severity of cirrhosis is associated with a reduction in HRV, 
which may be an indicator of poor prognosis and mortality for cirrhosis.
Thus, various studies have shown that AD does occur in cirrhosis and has a positive correlation with 
increasing  severity  of  the  underlying  liver  disease.  With  increasing  liver  disease,  there  is  an  over 
activity of the sympathetic tone accompanied with a decrease in the parasympathetic tone. Also, there 
is reduced heart rate variability with increasing severity of cirrhosis liver.
ANS dysfunction and cholelithiasis
Chawla  et  al.  studied  the  contribution  of  autonomic  neuropathy to  the  formation  of  gallstones  or 
gallbladder disease (due to impaired gallbladder emptying) in 123 patients (Child classes: A, 40; B, 45; 
C, 35) with cirrhosis liver. In all, 54 patients had gallstones and an additional 22 patients had other 
gallbladder disease (cholecystitis,  common bile duct stones, or debris).  Autonomic neuropathy was 
seen in 97 patients (one abnormal test in 48 and two or more in 49). The prevalence of gallstones was 
similar in Child A (57%), Child B (64%), and Child C (63%) cirrhosis. The gallstones or gallbladder 
disease  was  not  increased  in  women,  blacks,  diabetics,  or  alcoholic  cirrhotics.  The  prevalence  of 
gallbladder disease was increased in patients with autonomic neuropathy (51% vs 35%, P = 0.08); in 
patients with Child C cirrhosis, gallstones (P = 0.018) and gallbladder disease (P = 0.03) were seen 
more commonly in patients with autonomic neuropathy. Thus, the authors concluded that autonomic 
neuropathy may contribute to the formation of gallstones in patients with advanced cirrhosis, perhaps 
by impairing gallbladder and sphincter of Oddi dysmotility.
ANS dysfunction and variceal bleed.
Varghese  at  al  (11),  studied  the  influence  of  autonomic  dysfunction  on  the  variceal  bleed  (using 
standard ANS function tests)  in fifty cirrhotics (variceal bleeders:  34) belonging to  either sex and 
Childs B class. True AD was noted in 10 patients i.e. 20%.  Parasympathetic dysfunction alone was 
positive in 19 (38%) and sympathetic in 10 patients (20%). The E:I ratio (p < 0.001) and an increase in 
diastolic  B.P.  during  sustained  hand  grip  (p  <  0.04)  were  significantly  positive  amongst  variceal 
bleeders.  They concluded that  ‘True’  autonomic dysfunction can predispose a  cirrhotic  to  variceal 
bleed. It was postulated that, in presence of AD, a variceal bleed may fail to elicit the compensatory 
cardiovascular  reflex response and may cause an inappropriate  pooling of  blood in  the splanchnic 
circulation, thereby increasing the risk of further variceal bleed.
Effect of postural variation on cardiovascular autonomic responses:
Laffi  et  al  (37),  performed  a  study  on  the  effects  of  passive  head  tilting  on  the  cardiovascular 
autonomic responses,  in 15 cirrhotic patients with ascites and in 13 healthy subjects,  using heart rate 
variability  analysis  and  measurement  of  plasma  norepinephrine  levels.  In  the  supine  position,  no 
significant differences in the Power Spectral Analysis data (LF, HF) were observed between the control 
subjects and cirrhotic patients, who had higher plasma norepinephrine levels. In healthy subjects, tilting 
was associated with an increase in the LF and arterial pressure and a decrease in the HF. In contrast, 
patients  with  cirrhosis  showed  a  decrease  of  both  LF  and  HF.  Consequently,  the  LF/HF  ratio 
significantly increased in healthy subjects,  whereas it  was unchanged in cirrhotic patients. The LF 
component  of  the  diastolic  pressure  also  decreased  during  tilting  in    cirrhotic  patients.  Plasma 
norepinephrine increased after tilting in both groups. They concluded that the autonomic responnse to 
passive tilting is impaired in cirrhotic patients with ascites at both the cardiac and vascular levels, as a 
result  of  an  altered  sympatho-vagal  balance,  with  reduced  sympathetic  predominance.  They  also 
postulated that since these alterations occurred despite an appropriate response to the tilting of plasma 
norepinephrine, it pointed to a receptorial or postreceptorial site of the autonomic impairment. 
More recently Moller et al (64),  studied the humoral and central hemodynamic responses to changes 
with posture in 23 patients with cirrhosis (Child-Pugh class B/C: 21) and 14 healthy controls in the 
supine position and after 60° passive head-up tilting for a maximum of 20 minutes. After the head-up 
tilting, the central blood volume (CBV) decreased in both groups, but the decrease was significantly 
smaller in patients than in controls. The absolute increases in circulating norepinephrine and renin after 
head-up tilting were significantly higher in the patients than in the controls. They concluded that head-
up tilting decreases the central blood volume less in patients with cirrhosis, and it might be because of a 
differential regulation of central hemodynamics in patients with cirrhosis, with a higher activity of the 
RAAS.
ANS function after liver tansplantation
Though, autonomic dysfunction is a well recognized complication of end-stage liver disease (ESLD), but there is little 
information on how liver transplantation (LT) affects this problem. Carey et al (65), prospectively evaluated autonomic 
function in patients with ESLD before and after LT. Autonomic reflex screen (ARS) was performed on 30 patients with 
ESLD prior to transplantation. A 10-point composite autonomic score (CAS) was calculated from these data. ARS was 
repeated after LT, and these scores were compared with the pre-LT ARS. Thirty patients (25 male, 5 female) with cirrhosis 
that were listed for LT were enrolled in the study and underwent ARS prior to LT. The average age was 55.4 ± 9.1 years. 
Indications for LT included hepatitis C virus (14), cryptogenic cirrhosis (5), alcoholic cirrhosis (4), and other (7). The mean 
native Model for End-Stage Liver Disease (MELD) score at ARS was 17.0 ± 5.0. Prior to LT, 86.7% of patients had 
evidence of autonomic dysfunction. Mean CAS was 2.7 ± 2.2. Sudomotor function was disturbed in 66%, parasympathetic 
function was disturbed in 57%, and adrenergic function was disturbed in 37%. There was no relationship between pre-LT 
CAS and age, gender, diabetes, etiology of liver disease, or MELD score. Twenty-one patients (17 male, 4 female) had 
repeat ARS a mean of 9 ± 6.2 months after LT. The mean native MELD score at the time of ARS testing was 18.1 ± 4.3.  
Mean pre-LT CAS in this group was 3.0 ± 2.4. Pretransplant CAS was not related to age, gender, diabetes, or MELD score. 
Autonomic  dysfunction  improved  after  LT  (CAS  pre-LT,  3.0,  versus  CAS  post-LT,  1.9,  P =  0.02).  There  was  no 
relationship between post-LT CAS and age, gender,  diabetes,  etiology of liver disease, immunosuppression, or type of 
transplant. The authors concluded that, autonomic dysfunction is common in patients with ESLD, with over 86% having 
abnormal testing. Sixty-three percent of patients with cirrhosis with autonomic dysfunction show improvement after LT. 
Materials and Methods
Patients with a diagnosis of cirrhosis of the liver were included in the study group. The diagnosis of 
cirrhosis  was  made  by  clinical,  biochemical  and  ultrasound  criteria.  The  patients  were  grouped 
according to the modified Child-Pugh classification and also according to their bleed status (Variceal 
bleeders or non-bleeders)
Exclusion criteria were
• Use of Alcohol or tobacco products
• Diabetes, hypertension, coronary artery disease, rhythm or conduction disturbances
• Severe anemia (Hb < 7 gm/dl), electrolyte disorders
• Recent bleed (< 4 wk), thyroid disease, renal or cardiac failure 
• Known neurological disorder
• Hepatocellular carcinoma
Study period was from June 2007 to December 2008. HRV analysis was performed in the subjects 
between June and December 2007 and the patients were further followed up for a period of one year 
during outpatient visits or by telephonic calls at frequent intervals or till death. The cause of death was 
ascertained in each patient. 
Controls were age and sex matched healthy adults. The control group consisted of consorts or relatives 
of the patients.  
Ethical committee approval was obtained prior to the commencement of the study. 
Study protocol
The tests were carried out in the Electrophysiology lab, Department of Physiology, Stanley Medical 
College, Chennai.
All the recordings were done between 10.00 am and 1.00 pm. The laboratory environment was quiet 
with an ambient temperature between 25 - 28 degrees Celsius and the lighting subdued. Subjects were 
asked to empty their bladder before the tests. The tests did not involve intravascular instrumentation or 
administration of any drugs at any stage. Patients on Beta blockers were asked to withhold the drug for 
1  week  prior  to  testing.  Diuretics  were  stopped  on  the  day  of  the  testing.  No  patient  underwent 
paracentesis in the three weeks preceding the study.
Equipment
ECG was acquired using RMS Polyrite D hardware 2.2 (India), and instantaneous heart rate & RR 
intervals were continuously plotted using RMS 2.2 software on a Microsoft Window-based PC (The 
RMS polyrite software 2.2 helps to save multiple records and is provided with additional filter settings, 
calculation  tools,  automated  analysis  and  auto  report  generation)  (Figures  4  &  5).  Respiratory 
movements were recorded using a respiratory belt which detected both inspiration and expiration.
Measurement of HRV
The subjects were made to sit in the lab for 10min to get accustomed to the  new environment after 
emptying the urinary bladder, with a prior instruction of not to have anything by mouth for 1½ hours 
before test.  They were also instructed not to  have tea or coffee on the morning of the test.  After 
obtaining an informed consent and explaining about the procedure, the test was carried out as follows -
1) Electrodes were placed in the left and right shoulder and in the right leg. 
2) Respiratory belt was tied around the chest at the level of nipple to record respiratory movement.
3) The electrodes and the respiratory belt were connected to RMS polyrite D equipment. 
4) ECG was recorded for 10 minutes to determine the HRV at supine rest with the eyes closed with 
normal quite respiratory movement (12-16/min).
5) After recording in the supine position the subjects were asked to stand without support on a wooden 
plank and the recordings were repeated. 
Technique of Heart Rate Variability Analysis:
The ECG recording was checked for artifacts and ectopics. Recordings which showed such conduction 
disturbances were excluded. A 5-minute interval in the recording for selected for analysis of the data in 
the time domain (Mean R-R interval & Standard deviation of N-N intervals) and frequency domain 
[Low Frequency (LF) & High frequency (HF) {in power and normalized units (n.u)} and LF/HF ratio] 
analysis. (Fig 6)
All  the derivations  complied  with the  standards  recommended by the Task force  of  the  European 
Society of Cardiology and the North American Society for Pacing and Electrophysiology (12).
Statistical analysis
Data  were  expressed  as  Mean  ±  standard  deviation.  Statistical  analyses  were  carried  out  using 
Independent sample t test or one-way ANOVA test, where appropriate. P value < 0.05 was considered 
as significant. 
Observation and Results
51 patients were enrolled in the study. 13 patients were later excluded (Not co-operative for HRV 
analysis: 3; Alcohol consumption: 5; Ectopic beats/Movement artifacts: 3).
38 cirrhotic men with an age range between 20-62 years were finally included for analysis.  
The etiology of cirrhosis was Hepatitis B: 15; Hepatitis C: 11; Wilson disease: 2 and Cryptogenic 
cirrhosis: 10. (Table 5)
Table 5: Characteristics of the study population
Variable Number
No. of patients 38
Variceal bleed 19
Etiology
    Hepatitis B 15
    Hepatitis C 11
    Wilson disease 2
    Cryptogenic 10
Child Class A/B/C 6/19/13
Survivors 26
Cause of death
    Variceal bleed 5
    Spontaneous Bacterial Peritonitis 4
    Hepatoma 2
    Leptospirosis with renal failure 1
6 patients belonged to Child-Pugh (CP) class A, 9 to CP class B and 13 to CP class C. 18 patients 
(belonging to CP class B & C) had ascites requiring diuretics for control. 19 patients each were variceal 
bleeders and non-bleeders. 
All patients were followed up till the end of the study period. 12 patients passed away on follow up. 
The causes of death were-  Variceal bleed: 5 patients; Spontaneous Bacterial Peritonitis: 4 patients; 
Hepatoma: 2 patients and Leptospirosis with renal failure: 1 patient. (Table 5). Symptoms of autonomic 
dysfunction (postural dizziness) were present in 6 patients (Child Class B: 3; Class C: 3)
HRV analysis 
Cases vs Controls
Table 6: Cases vs Controls (Supine position)
Cases (38) Controls (22) P value
Mean RR 0.82± 0.14 0.88 ±0.13 0.088
SDNN 22.42± 13.6 42.31 ±19.07 0.000
LF (power) 19.0 ±15.6 14.06 ±9.05 0.181
HF (power) 12.64 ±15.69 38.4 ±15.95 0.853
LF (nu) 67.86 ±16.38 57.91 ±17.25 0.03
HF (nu) 33.5 ± 17.82 41.97 ±17.24 0.62
LF/HF 2.25 ±3.07 1.91 ±1.56 0.627
Cirrhotics have a significantly lower SDNN (implying reduced HRV and a decreased parasympathetic 
tone); higher LF (n.u) & LF/HF ratio in supine (Increased sympathetic tone) posture.
Table 7: Cases vs Controls (Upright position)
Cases (38) Control (22) P value
Mean RR 0.77 ±0.15 0.71± 0.1 0.062
SDNN 20.23 ±14.08 31.15± 10.92 0.003
LF (power) 17.19 ±13.6 28.47 ±15.44 0.005
HF (power) 10.85 ±11.25 8.5 ±5.91 0.368
LF (nu) 66.34 ±17.39 76.37 ±13.52 0.058
HF (nu) 32.28 ±16.2 21.13 ± 9.39 0.355
LF/HF 1.6 ±1.12 4.48 ±2.62 0.000
Cirrhotics  have  a  significantly lower  LF (power)  in  upright  position  ie,  lowered  sympathetic  tone 
compared to controls in upright posture. Also, they have a lower SDNN  (implying reduced HRV) 
compared to controls in the upright position. 
Table 8: Controls (Supine vs Upright posture)
Control (22) Supine Upright P value
Mean RR 0.88± 0.13 0.71± 0.10 0.00
SDNN 42.31± 19.70 31.15± 10.92 0.022
LF (power) 14.06 ±9.05 28.47 ±15.44 0.000
HF (power) 13.43 ±15.95 8.50 ±5.91 0.182
LF (nu) 57.9 ±17.25 76.37 ±13.52 0.001
HF (nu) 41.97 ±17.24 21.13 ± 9.39 0.001
LF/HF 1.91 ±1.56 4.48 ±2.62 0.000
As the control subject assumes an upright posture from the supine position, an increase LF (power and 
n.u) & LF/HF ratio with a decrease in SDNN, Mean R-R interval & HF (n.u) is observed.  These 
changes imply the physiological compensatory increase in sympathetic tone associated with a decrease 
in parasympathetic tone as one assumes an erect posture.
Table 9: Cases (Supine vs Upright posture)
Cases (38) Supine Standing P value
Mean RR 0.81 ± 0.14 0.77 ± 0.13 0.15
SDNN 22.42 ± 13.6 20.22 ± 14.08 0.49
LF (power) 19.0 ± 15.6 17.19 ± 13.6 0.59
HF (power) 12.64 ± 15.69 10.85 ± 11.25 0.57
LF (nu) 67.86 ± 16.38 66.34 ± 17.39 0.70
HF (nu) 33.5 ± 17.82 32.28 ± 16.2 0.32
LF/HF 2.25 ± 3.07 1.6 ± 1.12 0.22
On changing from the supine to  the upright  posture,  the decrease in  SDNN accompanied with an 
increase in LF power, observed in controls, was not seen in cirrhotics. 
Child-Pugh Class A vs B vs C
Table 10:  Child-Pugh Class A vs B vs C (Supine posture)
CP class A (6) CP class B (9) CP class C (13) P Value
Mean RR 0.83 ± 0.15 0.83 ± 0.15    0.79 ± 0. 13 0.65
SDNN 30.90 ± 16.08 21.16 ± 11.32 20.34 ± 15.08 0.25
LF (power) 38.63 ± 16.60 30.93 ± 13.68 29.97 ± 10.74 0.35 
HF (power) 18.82 ± 10.93 14.99 ± 18.60 6.36 ± 10.93 0.18
LF (nu) 50.78 ± 20.84 69.03 ± 14.05 72.6 ± 17.65 0.05
HF (nu) 32.35 ± 16.26 35.85 ± 19.28 30.6 ±.17.12 0.596 
LF/HF 2.48 ± 1.90 2.21 ± 3.34 2.2 ±.3.28 0.982
In  the  supine  posture,  there  was  an  increase  in  LF (n.u),  with  increasing  severity  of  cirrhosis  i.e 
increased sympathetic tone with advanced liver disease (CP class A vs B/C)
Table 11: Child-Pugh Class A vs B vs C (Upright posture)
CP class A (6) CP class B (9) CP class C (13) P Value
Mean RR 0.75 ± 0.12 0.8 ± 0.13 0.74 ± 0.13 0.42
SDNN 20.42 ± 8.39  21.31 ± 15.91 18.56 ± 14.05 0.87
LF (power) 20.42 ± 6.48 19.33 ± 17.05 12.58 ± 9.01 0.32
HF (power) 16.2 ± 6.52 11.08 ± 12.4 8.05 ± 10.9 0.35
LF (nu) 67.65 ±16.26 66.78 ± 16.70 69.54 ±17.16 0.90 
HF (nu) 39.6 ± 20.31 30.82 ± 14.09 31.02 ± 17.54 0.49
LF/HF 1.17 ± 0.41 1.92 ± 1.26 1.32 ± 1.04 0.20
No significant difference in the HRV parameters with increasing severity of cirrhosis (CP class A vs B 
vs C)   in the upright posture (both SNS & PNS function)
Survivors vs non-survivors
Table 12: Survivors vs non-survivors (Supine position)
Survivors (26) Non Survivors (12) P value
Mean RR 0.83 ± 0.15 0.79 ± 0.12 0.524
SDNN 21.98 ±  14.42 23.35 ± 12.18 0.777
LF (power) 17.30 ±14.22 22.68 ± 18.36 0.329
HF (power) 9.43 ±  11.25
 
19.61 ± 21.52
  
0.145
LF (nu) 69.99 ± 14.49  63.25 ± 19.79 0.244
HF (nu) 29.91 ± 14.52 35.85 ±  22.20 0.300
LF/HF 2.26 ± 2.91 2.23 ± 3.53 0.978
No significant difference in the HRV parameters (both sympathetic and parasympathetic function) was 
observed between and survivors and non-survivors in the supine position.
Table 13: Survivors vs non-survivors (Upright position)
Survivors (26) Non Survivors (12) P value
Mean RR 0.781 ± 0.13 0.746 ± 0.129 0.45
  SDNN 20.34 ± 15.41 18.90 ± 11.15 0.70
LF (power) 16.89 ± 14.73 17.85 ± 11.31 0.84
HF (power) 10.06 ± 10.24 12.56 ± 13.52 0.53
LF (nu) 67.88 ± 15.92 63.01 ± 20.58 0.43
HF (nu) 32.4 ± 15.83 32.02 ± 17.69 0.95
LF/HF 1.67 ± 1.22 1.43 ± 0.89 0.55
No significant difference in the HRV parameters (both sympathetic and parasympathetic function) was 
observed between and survivors and non-survivors in the upright position.
Bleeders vs Non-bleeders
Table 14: Bleeders vs Non-bleeders (Supine position)
Supine Non-Bleeders (19) Bleeders  (19) P value
Mean RR 0.80 ± 0.16 0.83 ± 0.121 0.488
SDNN 23.25 ± 14.45 21.58 ± 13.04 0.711
LF (power) 22.17 ± 14.15 15.83 ± 16.69 0.214
HF (power) 12.21 ± 13.86 13.08 ± 17.70 0.866
LF (nu) 69.18 ± 15.97 66.54 ± 17.12 0.626
HF (nu) 30.7947 ± 15.99 36.21 ± 19.28 0.300
LF/HF 3.07 ± 3.99 1.43 ± 1.44 0.102
No significant difference in the HRV parameters (both sympathetic and parasympathetic function) was 
observed between bleeders and non-bleeders in the supine postion.  
Table 15: Bleeders vs Non-bleeders (Upright position)
Standing Non-Bleeders (19) Bleeders  (19) P value
Mean RR 0.76 ± 0.15  0.78 ± 0.11 0.60
SDNN 21.73 ± 16.72 18.9 ± 11.8 0.55
LF (power) 18.41 ± 13.12 15.89 ± 14.87 0.59
HF (power) 13.79 ± 13.2 8.46 ± 8.81 0.16
LF (nu) 63.97 ± 18.3 67.56 ± 16.65 0.54
HF (nu) 36.16 ± 18.21 29.56 ± 13.61 0.22
LF/HF 1.4 ± 1.14 1.78 ± 1.15 0.32
No significant difference in the HRV parameters (both sympathetic and parasympathetic function) was 
observed between bleeders and non-bleeders in the upright position. 
Discussion
Autonomic dysfunction is commonly noted in patients with chronic liver disease and increases with 
worsening liver dysfunction (10, 59). 
Autonomic dysfunction has been correlated with mortality (9, 10, 13, 59) and variceal bleed (11) in 
patients with cirrhosis liver. Rangari et al (53), in the only study on heart rate variability in patients 
with liver cirrhosis from India, used time domain methods for HRV analysis. They showed that four 
out of the five time domain measures were abnormal in patients with liver cirrhosis. 
The present study, based on both time domain (Mean R-R & SDNN) and frequency domain measures 
(LF & HF) of HRV analysis, has shown that autonomic function is significantly impaired in patients 
with cirrhosis of the liver. 
In the supine position,  cirrhotics had a significant increase in their  sympathetic tone (compared to 
controls) as evidenced by an increase in the LF (n.u). They also had a reduced heart rate variability 
(reduced SDNN) implying reduced parasympathetic tone. Thus, at rest in supine position, cirrhotics 
have a relatively increased sympathetic and a decreased parasympathetic tone. This is consistent with 
the observation of a hyperdynamic circulation in cirrhosis liver with an activation of the RAAS (Renin-
Angiotensin-Aldosterone system) and the SNS (Sympathetic nervous system) pathway (20). This also 
correlates with other studies on heart rate variability in patients with cirrhosis of the liver (60, 62). 
As  the  cirrhotic  patient  assumes  an  upright  position,  the  compensatory  changes  in  the  autonomic 
function in the form of a raise in sympathetic and a relative fall in parasympathetic tone (observed in 
controls), is not evident. 
In a similar study by Laffi et al (37), on the effect of passive head tilting in patients with liver cirrhosis, 
it was observed that there was no difference in the power spectral analysis data (LF and HF) between 
controls and cirrhotics in the supine position. However, cirrhotics had a higher plasma norepinephrine 
levels in the supine position. On passive head tilting, observations similar to the present study were 
made. 
With worsening liver dysfunction (CP class A vs B/C), an increase in the LF (n.u) was observed in the 
supine position, implying an increase in the sympathetic tone. This is consistent with the observation 
that the splanchnic arteriolar vasodilatation and hyperdynamic circulation seen in advanced cirrhosis 
leads to the activation of the SNS and the RAAS pathway (20). 
Varghese et al (11) assessed the ANS function in 2 groups of cirrhotics: those with and without a 
history of variceal bleed. It was found that AD was significantly present in cirrhotics with a history of 
variceal bleed. However, assessment of the ANS function was using the standard tests (39) and heart 
rate variability analysis was not employed. In our study, there was no significant difference in the HRV 
parameters between variceal bleeders and non-bleeders. 
Presence of autonomic neuropathy has been regarded as a poor prognostic indicator with increased 
mortality noted in patients with AD (10, 12, 59). In the present study, however, there was no difference 
in the HRV parameters between survivors & non-survivors and AD did not predict mortality in the 
study group.
The  causes  of  death  in  our  study group  were-  Variceal  bleed:  5  patients;  Spontaneous  Bacterial 
Peritonitis  (SBP):  4  patients;  Hepatoma:  2  patients  and Leptospirosis  with  renal  failure:  1  patient. 
Variceal bleed was the most common cause of death and as mentioned above, there was no difference 
in  the  HRV parameters  between bleeders  & non-bleeders  in  our  study.  Hepatitis  B was the  most 
common etiology in our study group and it is known that hepatocellular carcinoma can occur in such 
patients at a less advanced stage of chronic liver disease (66). Leptospirosis, endemic in Chennai city 
(68), was the cause of death in one patient. SBP, a complication of advanced chronic liver disease was 
the cause of death in only 4 out of the 12 patients. Hence, not all deaths in the study group were related 
to end stage liver disease, which could explain the reason for no significant difference in the HRV 
parameters between survivors and non-survivors. Also, our study group consisted of only 38 patients 
with a follow up period of one year.  Further  studies  with a larger  study group and with a longer 
duration of follow up might probably yield a positive correlation between autonomic dysfunction and 
mortality in patients with chronic liver disease.
Summary
Figure 4: Parasympathetic and Sympathetic tone in controls and patients with cirrhosis (Child’s 
class A/B/C)
Parasympathetic tone Sympathetic tone
Controls supine position
Controls upright position
Cirrhotics supine position
Cirrhotics upright position
Child class A vs B/C
Controls in the supine position have a balanced sympathetic and parasympathetic tone. On assuming an 
upright  posture,  there  is  a  physiological  increase  in  the  sympathetic  and  a  decrease  in  the 
parasympathetic tone in the control group. 
Cirrhotics,  in  the  supine  position,  have  a  relatively  increased  sympathetic  compared  to  the 
parasympathetic tone. On assuming an upright posture, the physiological increase in the sympathetic 
and a decrease in the parasympathetic tone (observed in controls), is not seen in cirrhotics. 
With worsening liver dysfunction (Child class A vs B/C), there is an increase in the sympathetic tone.
Conclusion
HRV analysis is a simple, noninvasive test to assess the cardiovascular autonomic function in patients 
with chronic liver disease .
Patients with liver cirrhosis have significantly reduced heart rate variability (decreased parasympathetic 
activity) and an increased sympathetic tone in supine posture. 
Cirrhotics have an abnormal homeostatic response to standing with no increase in sympathetic tone in 
the upright posture.
With worsening Child Pugh class (A vs B/C), there is an increase in autonomic dysfunction, with an 
increased activity of the sympathetic component. 
There were no significant differences in HRV parameters between bleeders versus non-bleeders and 
survivors versus non-survivors.
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                                                                            Proforma
Name:           Age/Sex: 
Address/ Contact No: MGE No:  
Etiology: HBV/HCV/ Wilson’s disease/ Others (Specify)             Child Pugh Score:
Clinical features: 
Symptoms Yes/No Symptoms Yes/No
Ascites/ Pedal Edema Altered sensorium
Pain Abdomen GI bleed
Jaundice Coagulopathy
Oliguria Others (Specify)
Autonomic symptoms 
(postural dizziness)
Co-morbidity (DM, HTN, 
CAD, others specify)
Examination: 
Jaundice/ Pallor/ Pedal edema/ Spider naevi
Vital Signs: PR: BP: Temp:
Abdomen: Liver: Spleen: Ascites: 
CVS/RS: 
CNS: Asterixis/ Hep. Encephalopathy: 
Investigations
Hb:                                                                          B Urea: 
TC:                                                                          S Creatinine:
DC:                                                                          S Electrolytes:
ESR:                                                                        B Sugar: 
Platelets :                                                                 PT (T/C):
MCV/MCH/MCHC :             INR:
S Bilirubin (T/D): USG Abdomen/ PV Doppler:
AST/ALT
SAP/ GGT: CXR:
Alb/ Globulin: Ascitic fluid cell count:
OGD: Esophageal varices: Gastric varices:
HRV analysis:
Mean RR interval:
SDNN: 
LF (power):
HF (power):
LF (n.u)                                                                  
HF (n.u)
LF/ HF ratio: 
Follow Up: 
Alive/ Dead:
Cause of death (when applicable);
APPENDIX D
Consent Form
I,  Mr.  ______________________________,  understand  that  Dr.  xxxxxxx,  a  postgraduate 
student in Stanley medical college and hospital, Chennai, is doing a study on heart rate variability. I am 
given to understand that these tests will assess the functioning of my heart and blood vessels and the 
nerves regulating them. These tests are simple; involve taking ECGs, blood pressure and respiratory 
movements in lying and standing position. They do not involve injections or taking any medicines and 
are risk free. I have been familiarized with the testing procedures. I am participating in this study 
willingly.  I have not been forced to do so.  I have also been told clearly that I could withdraw from this 
study without any prejudice.
Date :
Signature :  
Figure 4: Electrophysiology Lab with HRV recording software
Figure 5: Computerized digital recording of HRV
